SynaptixBio Ltd gets FDA ODD for leukodystrophy
Using antisense oligonucleotides (ASO) to silence the beta tubulin 4a gene, Oxford-based SynaptixBio Ltd received its first ODD in early 2023 for a...
Gut bacteria seed autoimmunity-inducers
A unique mechanism, reported by an Irish-French research team underscores an emerging theme in microbiome research: that disruptions to gut bacteria...
Curve Therapeutics raises £40.5m in Series A financing
New investors Columbus Venture Partners and British Patient Capital and founding investor Advent Life Sciences as well as seed investor Epidarex...
AmphiStar BV secures €6m to expand production
The infusion of €6m in new capital from ECBF, Qbic III and FFTF will empower AmphiStar to kickstart commercial biosurfactant production in...
Bayer's Ask Bio unit starts Phase II heart failure gene therapy
The Phase II trial called GenePHIT is the largest adaptive, double-blind, placebo-controlled, randomised, multicentre trial ever to evaluate the...
Forbion participates in US financing rounds
Forbion is throwing a few million into the ring in order to participate in oversubscribed financing rounds in the USA. Both Series B financings have...
Cambridge university spin-out HutanBio Ltd bags £2.25m seed financing
HutanBio, a Malaysian spin-out from scientists at Cambridge University, UK, has bagged a first tranche of seed investment from London-based Clean...